Cresci B, Cosentino C, Monami M, et al. - In this network meta‐analysis (NMA) of randomized controlled trials, researchers sought to compare different metabolic surgery (MS) techniques vs medical therapy (MT) in individuals with type 2 diabetes (T2D), with a duration of ≥ 24 weeks. The 24 retrieved trials involved 1,351 patients (1,014 with MS and 337 with MT). Data reported that the mean baseline BMI was 36.8 kg/m². MS was related to significantly higher reductions in HbA1c and FPG, and greater remission of diabetes compared with MT. A significant reduction in HbA1c was found with one‐anastomosis gastric bypass and sleeve gastrectomy in the NMA. All surgical procedures, excluding greater curvature plication and laparoscopic adjustable gastric banding, have been associated with a major rise in diabetes remission. All procedures have been linked to a reduction of BMI. Metabolic surgery is an promising alternative for treating T2D, but additional data are needed to demonstrate its long-term effectiveness and safety. Present data are not sufficient to change current guidelines that find MS in those with a BMI > 35 kg/m² to be a potential treatment for T2D.